Skip to content

Investors
Join Us

<img width="224" height="61" src="https://femasys.com/wp-content/uploads/2021/11/Femasys-Logo.svg" class="custom-logo astra-logo-svg" alt="Femasys Logo" decoding="async" />

About Us
Our Focus
Our Pipeline
Resources
Contact Us

About Us
Our Focus
Our Pipeline
Resources
Contact Us
Investors
Join Us

<img width="224" height="61" src="https://femasys.com/wp-content/uploads/2021/11/Femasys-Logo.svg" class="custom-logo astra-logo-svg" alt="Femasys Logo" decoding="async" />

About Us
Our Focus
Our Pipeline
Resources
Contact Us
Investors
Join Us

November 2022

Femasys Selected by BioSpace as a 2023 Best Places to Work

2022, Media / By lsc-webmaster

Femasys Targets Male Infertility with Updated Trial Design

2022, Media / By lsc-webmaster

Search

Recent Posts

FemCerv®: Well-designed technology that can minimize patient discomfort
The Post-Roe Fertility Journey
US biomedical company launches intrauterine device for tubal evaluation
Femasys Selected by BioSpace as a 2023 Best Places to Work
Femasys Targets Male Infertility with Updated Trial Design

Recent Comments

No comments to show.

Archives

April 2023
February 2023
January 2023
November 2022
October 2022
September 2022
August 2022
July 2022
June 2022
May 2022
February 2022
January 2022
December 2021
October 2021
July 2021
June 2021
May 2021

Categories

2021
2022
2023
Board of Directors
Leadership
Media
Video

Privacy & Terms
Patents
Accessibility

Copyright © 2023 Femasys Inc.

FemaSeed, FemBloc, FemCath, FemCerv, and FemVue are registered trademarks of Femasys Inc. FemEMB is a trademark of Femasys Inc.